Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Allergy Therapeutics ( (GB:AGY) ) has provided an announcement.
Allergy Therapeutics has published the notice of its 2025 Annual General Meeting, following release of its annual report and accounts for the year ended 30 June 2025, with meeting documents now available to shareholders via the company’s website. The company is asking shareholders to approve the appointment of two new board members, former HSBC vice chairman Helge Weiner-Trapness as executive director and chief strategy officer, and Adicon CFO Lawrence Allen Wang as a non-executive director, both bringing substantial investment banking and healthcare experience in Asia. Management believes these additions will support Allergy Therapeutics’ exploration of a potential dual primary listing on the Hong Kong Stock Exchange alongside its AIM quote and underpin its strategy to expand in Asia and strengthen its position as a global player in allergy treatments.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The overall stock score is primarily impacted by the company’s poor financial performance, which poses significant risks. Despite strong technical indicators suggesting bullish momentum, the overbought condition may lead to a correction. The negative P/E ratio and lack of dividend yield further detract from the stock’s attractiveness.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is a UK-headquartered international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders, including aluminium-free allergy immunotherapies that aim to cure disease. The group markets proprietary and third-party products through subsidiaries and branches in nine major European countries and via distributors in a further four markets.
Average Trading Volume: 420,856
Technical Sentiment Signal: Buy
Current Market Cap: £730.8M
Find detailed analytics on AGY stock on TipRanks’ Stock Analysis page.